Study of Varencline Effects on Cigarette Smoking Reward and Craving During a Model of Brief Quit Attempt

Phase 1

Withdrawn

• Conditions: Nicotine Dependence
• Interventions: Drug: varencline; Drug: placebo

• Registration Number: NCT00571805
• Lead Sponsor: NYU Langone Health

Brief Summary

Study of varenicline 2.0 mg/day treatment for 2 weeks with smoking test done in laboratory on Day 8 and a 1 week quit attempt from Day 8-14.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-09
• Study First Submitted: 2007-12-11
• Study First Submitted QC: 2007-12-11
• Study First Posted: 2007-12-12
• Status Verified: 2015-04
• Last Update Submitted: 2015-04-08
• Last Update Posted: 2015-04-09

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• At least 10 cigarettes/day
• Interest in quitting smoking
• Willgness to comply with overnight smoking abbstiennce period followed by lab smoking test

Exclusion Criteria

• Pregnancy
• Axis I psychiatric disorder which require treatment with psychoactive medication and would make study compliance difficult.
• Clinically significant medical condition in opinion of study clinician
• Drug or alcohol dependence inlast 12 months
• Use of other smoking cessation medications ot treatment progams in last 2 months

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1	varencline	Varenicline
2	placebo	placebo

Primary Outcome Measures

Name	Time	Method
Smoking reward	laboratory test

Secondary Outcome Measures

Name	Time	Method
1 week abstinence induced craving and reward	Day 8, 9, 11 and 14 questionaires

Trial Locations

Locations (1)

VA New York Harbor Healthcare System, MHAD clinic; 🇺🇸 New York, New York, United States